Nabeel Saghir, MD
Cardiovascular Disease · New Orleans, LANPI 1417487323
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.5%), food and beverage and grants — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Medtronic at 32.5% of the total. 2025 is the largest year on record at $16,846, 3.3 times the $5,132 reported in 2021. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $154.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Abbott$13K
- Boston Scientific$12K
- Biotronik Inc.$3K
- Biosense Webster, Inc.$932
- Abiomed$703
- plus $3K from 15 others
What the payments were for
- Grants$5,00010%
- Travel & lodging$28,18358%
- Food & beverage$15,00431%
- Education$8242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 92 | $15,932 |
| Abbott | 83 | $13,392 |
| Boston Scientific | 61 | $11,522 |
| Biotronik Inc. | 23 | $3,217 |
| Biosense Webster, Inc. | 15 | $932 |
| Abiomed | 9 | $703 |
| Medical Device Business Services, Inc. | 1 | $516 |
| Amgen | 5 | $471 |
| Pfizer | 7 | $386 |
| AOP Health US, LLC | 1 | $349 |
| E.r. Squibb & Sons, L.L.C. | 4 | $322 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $216 |
| Impulse Dynamics (USA) Inc. | 2 | $199 |
| Kestra Medical Technology Services, Inc. | 3 | $160 |
| Cardiovascular Systems Inc. | 1 | $140 |
| Endologix LLC | 1 | $137 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $114 |
| Itamar Medical Inc | 1 | $104 |
| AstraZeneca | 3 | $51 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Farapulse$5,747
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$4,530
- ENSITE PRECISION$2,206
- EnSite Precision Cardiac Mapping System$1,671
- AVEIR$1,558
- HeartMate Touch$1,091
- Carto 3$1,034
- Rivacor$992
- Edora$992
- Acticor$992
- Solia$827
- BioMonitor$827
- Rapiblyk$699
- WATCHMAN Access System$636
- Impella$470
- Repatha$454
- Sentus$390
- Plexa$390
- Acticor 7 VR-T DX$364
- CARDIOMEMS$340
How this compares
$49,011 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 17 | $20,645 |
| EliquisApixaban | 17 | $17,468 |
| EntrestoSacubitril/Valsartan | 21 | $16,892 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 68 | $934 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $624 |
| Oseltamivir Phosphate | 19 | $454 |
| Metoprolol Succinate | 44 | $436 |
| Fluticasone Propionate | 32 | $321 |
| Metronidazole | 17 | $254 |
| Azithromycin | 68 | $217 |
| Rosuvastatin Calcium | 20 | $202 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $189 |
| Atorvastatin Calcium | 30 | $154 |
| Paxlovid (Eua)Nirmatrelvir/Ritonavir | 15 | $152 |
| Doxycycline Hyclate | 17 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid (Eua), Paxlovid | $386 | $17,62078 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
- Frank WilklowNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.